Shareholder equity has deteriorated to a negative $12.0M as of 2026Q1, reflecting the structural erosion of the capital base during the search for a merger target.
| Total Current Assets | 451.9K | 181.18K | 1.06M |
| Cash & Short-Term Investments | - | - | - |
| Cash Only | - | - | - |
| Short-Term Investments | - | - | - |
| Accounts Receivable | - | - | - |
| Days Sales Outstanding | - | - | - |
| Inventory | - | - | - |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | -247.43M | -245.3M | 0 |
| Total Non-Current Assets | 247.62M | 245.45M | 235.58M |
| Property, Plant & Equipment | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | - | - | - |
| Total Assets | 248.07M | 245.63M | 236.64M |
| Asset Turnover | 0.00x | - | - |
| Asset Growth % | 3.82% | 3.8% | - |
| Total Current Liabilities | 1.53M | 791.14K | 109.18K |
| Accounts Payable | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | - | - |
| Other Current Liabilities | 1.53M | 791.14K | 0 |
| Current Ratio | 0.30x | 0.23x | 9.67x |
| Quick Ratio | 0.30x | 0.23x | 9.67x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 10.95M | 10.95M | 10.95M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | - | - |
| Deferred Tax Liabilities | 0 | - | - |
| Other Non-Current Liabilities | - | - | - |
| Total Liabilities | 12.48M | 11.74M | 11.06M |
| Total Debt | 0 | 0 | 0 |
| Net Debt | -266K | -30.15K | -850.34K |
| Debt / Equity | -0.00x | - | - |
| Debt / EBITDA | -0.00x | - | - |
| Net Debt / EBITDA | 0.14x | - | - |
| Interest Coverage | - | - | - |
| Total Equity | -12.03M | -11.56M | 225.58M |
| Equity Growth % | -105.28% | -105.12% | - |
| Book Value per Share | -0.52 | -0.50 | 11.59 |
| Total Shareholders' Equity | -12.03M | -11.56M | 225.58M |
| Common Stock | 495.69M | 491.08M | 235.53M |
| Retained Earnings | -12.03M | -11.56M | -9.95M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
Sponsor dependency and liquidation
As reported in financial statements, the company's equity has shifted from a positive $227.9M in 2025Q1 to a negative $12.0M by 2026Q1, reflecting the structural erosion of shareholder value as the entity consumes its capital base while failing to secure a definitive business combination.
The transition into negative equity territory suggests that the company is effectively operating on borrowed time and sponsor goodwill. Investors should monitor this trend closely, as the persistent decline in net assets may indicate that the costs of maintaining the shell structure are outpacing the value of the trust assets.
Based on the 2026Q1 balance sheet, the company reports $247.9M in cash, yet this figure is misleading because the vast majority is restricted in a trust account, leaving the firm with minimal liquidity to cover ongoing administrative expenses and due diligence requirements for potential targets.
The current ratio of 0.30 in 2026Q1 highlights a severe mismatch between short-term obligations and available working capital. This liquidity profile suggests that the firm is highly dependent on external sponsor support to remain a going concern until a merger is finalized.
According to quarterly filings, the company's retained earnings have steadily declined to -$12.0M as of 2026Q1, a direct consequence of the persistent administrative and legal costs incurred during the search for a life sciences target without any offsetting revenue generation to replenish the capital base.
The accumulation of these losses underscores the high cost of maintaining a public shell entity. This trend warrants further investigation into whether the sponsor will be required to inject additional capital to prevent a total depletion of the firm's non-restricted equity before the merger window closes.
As indicated by the provided financial data, the company's total assets of $248.1M are almost entirely comprised of restricted trust funds, which obscures the underlying reality that the firm lacks the operational assets or revenue-generating capacity typical of a viable, long-term life sciences business entity.
The reliance on interest income from the trust account to offset administrative expenses creates a false sense of stability. Investors should be wary that the headline asset figure does not represent capital available for growth, but rather a pool of funds that may be redeemed by shareholders.
Quick answers to the most common questions about buying LPAAW stock.
As of 2025, Launch One Acquisition Corp. (LPAAW) had total assets of $245.6M including $0.2M in current assets.
Launch One Acquisition Corp. (LPAAW) carries total debt of $0.0M. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Launch One Acquisition Corp. (LPAAW) has total shareholders' equity (book value) of $-11.6M ($-0.50 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Launch One Acquisition Corp. (LPAAW) reported a current ratio of 0.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.